Advaxis, Inc. (NASDAQ:ADXS) rose 7% during mid-day trading on Tuesday . The stock traded as high as $0.50 and last traded at $0.46. Approximately 3,411,426 shares were traded during trading, an increase of 152% from the average daily volume of 1,355,476 shares. The stock had previously closed at $0.43.

ADXS has been the subject of several research analyst reports. HC Wainwright reaffirmed a “hold” rating on shares of Advaxis in a research note on Wednesday, January 16th. Zacks Investment Research raised Advaxis from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Wednesday, February 20th. Finally, ValuEngine lowered Advaxis from a “buy” rating to a “hold” rating in a research note on Friday, January 25th.

The company has a market capitalization of $29.64 million, a PE ratio of -0.36 and a beta of 3.94.

Advaxis (NASDAQ:ADXS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.43. Advaxis had a negative return on equity of 101.51% and a negative net margin of 140.12%. The company had revenue of $19.69 million during the quarter. As a group, research analysts anticipate that Advaxis, Inc. will post -0.2 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its stake in shares of Advaxis by 48.3% in the 3rd quarter. Vanguard Group Inc now owns 2,630,658 shares of the biotechnology company’s stock valued at $2,473,000 after acquiring an additional 857,026 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Advaxis by 3.1% in the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 43,368 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Advaxis by 173.0% in the 3rd quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after acquiring an additional 755,352 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Advaxis by 2,468.2% in the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 355,415 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Advaxis by 740.4% in the 4th quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 155,246 shares during the last quarter. 22.47% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Advaxis (ADXS) Stock Price Up 7%” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/advaxis-adxs-stock-price-up-7/2902711.html.

Advaxis Company Profile (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: What do investors mean by earnings per share?

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.